Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater
Titel:
Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater
Auteur:
She, Longjiang Hu, Huabin Liao, Mengting Xia, Xuefeng Shi, Yin Yao, Linli Ding, Dong Zhu, Youwen Zeng, Shan Shen, Liangfang Huang, Jin Carbone, David P.